MedTrace Logo

Evaluation of the Efficacy for Sentinel Lymph Node Policy in Intermediate-risk Endometrial Carcinomas

NCT03677024 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2024-09-26

No results posted yet for this study

Summary

To evaluate the efficacy of sentinel lymph node policy in patients with intermediate-risk endometrial carcinomas

Conditions

  • Endometrial Endometrioid Adenocarcinoma

Interventions

PROCEDURE

SLN arm

Intra-operative SN mapping with indocyanin green: Intracervical injection will be performed by the surgeon. Sub-mucous injections will be performed with 50% diluted dye at 3 and 9 o'clock positions. 1ml injection contained infracyanine green will be injected deeply into the stroma of the cervix (1cm-depth), and another 1ml will be injected superficially (2mm-depth). The time between the injection and the search for SLN must be as soon as possible.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Xiaojun Chen, PhD · Obstetrics and Gynecology Hospital, Fudan University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-06
Primary Completion
2021-10-07
Completion
2021-10-07

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03677024 on ClinicalTrials.gov